[HTML][HTML] MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma
Bladder urothelial carcinoma (BLC) is one of the most common cancers in men, and its
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma
SY Sathipati, MJ Tsai, SK Shukla, SY Ho, Y Liu… - Scientific …, 2022 - scholar.nycu.edu.tw
Bladder urothelial carcinoma (BLC) is one of the most common cancers in men, and its
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
[引用][C] Author Correction: MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma
S Yerukala Sathipati, MJ Tsai, SK Shukla, SY Ho… - Scientific Reports, 2022 - nature.com
Author Correction: MicroRNA signature for estimating the survival time in patients with bladder
urothelial carcinoma Page 1 1 Vol.:(0123456789) Scientific Reports | (2022) 12:4990 …
urothelial carcinoma Page 1 1 Vol.:(0123456789) Scientific Reports | (2022) 12:4990 …
[HTML][HTML] MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma
SY Sathipati, MJ Tsai, SK Shukla, SY Ho, Y Liu… - Scientific …, 2022 - ncbi.nlm.nih.gov
Bladder urothelial carcinoma (BLC) is one of the most common cancers in men, and its
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma
SY Sathipati, MJ Tsai, SK Shukla, SY Ho… - Scientific …, 2022 - pubmed.ncbi.nlm.nih.gov
Bladder urothelial carcinoma (BLC) is one of the most common cancers in men, and its
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma.
MJ Tsai, SK Shukla, SY Ho, Y Liu, A Beheshti - Scientific Reports, 2022 - europepmc.org
Bladder urothelial carcinoma (BLC) is one of the most common cancers in men, and its
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma
S Yerukala Sathipati, MJ Tsai, SK Shukla… - Scientific …, 2022 - ui.adsabs.harvard.edu
Bladder urothelial carcinoma (BLC) is one of the most common cancers in men, and its
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma.
S Yerukala Sathipati, MJ Tsai, SK Shukla… - Scientific …, 2022 - search.ebscohost.com
Bladder urothelial carcinoma (BLC) is one of the most common cancers in men, and its
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma
SY Sathipati, MJ Tsai, SK Shukla, SY Ho… - Scientific …, 2022 - pubmed.ncbi.nlm.nih.gov
Bladder urothelial carcinoma (BLC) is one of the most common cancers in men, and its
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
MicroRNA signature for estimating the survival time in patients with bladder urothelial carcinoma.
S Yerukala Sathipati, MJ Tsai, SK Shukla… - Scientific …, 2022 - search.ebscohost.com
Bladder urothelial carcinoma (BLC) is one of the most common cancers in men, and its
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …
heterogeneity challenges the treatment to cure this disease. Recently, microRNAs (miRNAs) …